Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party? [0.03%]
套细胞淋巴瘤患者如何使用BTK抑制剂及其他新型疗法？我们都应该参加这场盛宴吗？
Andre Costa Meireles,Paloma Martinho Resende,Laura Korin et al.
Andre Costa Meireles et al.
Mantle cell lymphoma (MCL) has undergone a profound therapeutic transformation over the past 2 decades. Historically characterized by frequent relapse and limited survival, MCL outcomes have improved with the incorporation of high-dose cyta...
Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance [0.03%]
血小板增多表型在前纤维化原发性骨髓纤维症中的风险分层和预后意义
Chun-Hao Lin,Chun-Kuang Tsai,Te-Lin Hsu et al.
Chun-Hao Lin et al.
Background: Essential thrombocythemia, prefibrotic primary myelofibrosis (pre-PMF), and overt primary myelofibrosis are myeloproliferative neoplasms with overlapping clinical features but different prognoses. We investiga...
Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis [0.03%]
套细胞淋巴瘤无进展生存期与总生存期相关性：基于试验水平的替代终点分析
Alexander M Gorzewski,Christina Raker,Victoria A Gill et al.
Alexander M Gorzewski et al.
Introduction: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary end...
SOHO State of the Art Updates and Next Questions | Management of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [0.03%]
SOHO最新研究进展和下一步问题｜高危费城染色体阳性急性淋巴细胞白血病的治疗管理
Walid Macaron,Hagop Kantarjian,Elias Jabbour et al.
Walid Macaron et al.
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically associated with dismal outcomes. The introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs) transformed this disease, and more recently, chemother...
Outcomes of Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Over 70 Years of Age: A Comparative Analysis by Age Group [0.03%]
比较不同年龄组移植后结果：老年（＞70岁）急性髓系白血病和骨髓增生异常综合征患者移植物抗宿主病预防方案中联合移植后环磷酰胺的研究
Muhammad Umair Mushtaq,Muhammad Kashif Amin,Amir Kasaeian et al.
Muhammad Umair Mushtaq et al.
Background: We aimed to study outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients aged above 70 with using post-transplant cyclophosphamid...
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies [0.03%]
CARTITUDE研究中接受西妥昔珠单抗自体治疗复发/难治性多发性骨髓瘤患者的非ICANS神经事件的临床表现和管理
Paula Rodríguez-Otero,Jaime Gállego Pérez-Larraya,Yi Lin et al.
Paula Rodríguez-Otero et al.
B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). However, emerging non-immune effector cell-associated neurotoxicity s...
Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries [0.03%]
一线尼洛替尼与达沙替尼治疗新诊断的慢性期慢性髓性白血病：基于AIFA监测登记册的倾向评分分析
Massimo Breccia,Simone Celant,Fabrizio Pane et al.
Massimo Breccia et al.
Background: Time to treatment discontinuation (TTD) in chronic phase chronic myeloid leukemia (CML) adult Italian patients who started frontline dasatinib or nilotinib recorded in the Italian medicines agency (AIFA) monit...
The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan [0.03%]
从患者和治疗医师的角度看进展期无进展生存期的价值：美国、欧盟四国、英国、巴西和日本的研究成果
Aaron S Rosenberg,Thomas Chalopin,Alison Bulkley et al.
Aaron S Rosenberg et al.
Background: Treatment advancements in multiple myeloma (MM) have improved OS, but OS is a challenging endpoint for regulatory approvals as it both requires a prolonged follow-up period and is affected by subsequent therap...
Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic Leukemia [0.03%]
成人急性淋巴细胞白血病中 measurable residual disease 的检测与管理
Tamer Othman,Ibrahim Aldoss
Tamer Othman
During the past 3 decades, numerous studies have investigated measurable residual disease (MRD) detection methodologies and the clinical significance of MRD in acute lymphoblastic leukemia (ALL). These studies have consistently demonstrated...
SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets [0.03%]
新型疗法在T细胞急性淋巴细胞白血病中的应用：从CAR-T到新靶点
Ryan J Summers,Haley Newman,David T Teachey
Ryan J Summers
While outcomes for children and adolescents with T-cell acute lymphoblastic leukemia (T-ALL) have improved significantly with contemporary therapy, outcomes for newly diagnosed adults and all patients with relapsed or refractory (r/r) disea...